ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...

ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study Proof of concept that new class of lysin biologics has the potential to improve treatment outcomes in serious bacterial infections Exebacase demonstrated robust safety and tolerability profile ...

ContraFect to Present at Piper Jaffray Health Care Conference YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...

ContraFect Announces Third Quarter 2018 Financial Results YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...